<DOC>
	<DOCNO>NCT03027284</DOCNO>
	<brief_summary>The main purpose study evaluate tolerability merestinib monotherapy combination anti-cancer agent Japanese participant advance and/or metastatic cancer .</brief_summary>
	<brief_title>A Study Merestinib ( LY2801653 ) Japanese Participants With Advanced Metastatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Part A : Histological cytological evidence diagnosis cancer advance and/or metastatic ( solid tumor nonHodgkin 's lymphoma ) . Part B : Biliary tract carcinoma unresectable , recurrent , metastatic . The participant must receive prior systemic frontline therapy metastatic resectable disease . Part A : Measurable nonmeasurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 Cheson Criteria . Part B : Measurable disease define RECIST v1.1 . Adequate organ function include hematologic , hepatic renal . Eastern Cooperative Oncology Group ( ECOG ) scale 0 1 . Are able swallow tablet . For participant Part B , tumor tissue sample mandatory biomarker analysis . Males must agree use medically approve barrier contraceptive precaution study 3 month follow last dose study drug . Females childbearing potential : Must agree use medically approve contraceptive precaution study 3 month follow last dose study drug , must negative serum urine pregnancy test â‰¤7 day first dose study drug . A breastfeed woman must breastfeed . If female stop breastfeed enters study , breastfeed must cease day first study drug administration least 3 month last administration . Have serious preexist medical condition . Have chronic underlying infection . Have symptomatic central nervous system malignancy metastasis . Have active fungal , bacterial , and/or know viral infection . Part B : Have mix hepatocellular biliary tract carcinoma histology . Have liver cirrhosis ChildPugh stage B high , receive liver transplant . Have history congestive heart failure New York Heart Association ( NYHA ) class great 2 , unstable angina , recent history myocardial infarction , transient ischemic attack , stroke , arterial venous vascular disease . Have correct QT interval &gt; 470 millisecond calculate Fredericia equation . Have second primary malignancy , judgment investigator , sponsor may affect interpretation result . Have evidence clinically active interstitial lung disease ( ILD ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Neoplasm</keyword>
</DOC>